BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32156491)

  • 1. Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease.
    Goldberg H; Spratt D; Chandrasekar T; Klaassen Z; Wallis CJD; Santiago-Jimenez M; Fishbane N; Davicioni E; Noorani R; Ahmad AE; Herrera Cáceres JO; Alibhai S; Berlin A; Fleshner NE
    Eur Urol Focus; 2021 Jul; 7(4):797-806. PubMed ID: 32156491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
    Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
    Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
    Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
    Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
    Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
    Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
    Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW
    Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the Decipher genomic classifier among men with prostate cancer in the United States.
    Zaorsky NG; Proudfoot JA; Jia AY; Zuhour R; Vince R; Liu Y; Zhao X; Hu J; Schussler NC; Stevens JL; Bentler S; Cress RD; Doherty JA; Durbin EB; Gershman S; Cheng I; Gonsalves L; Hernandez BY; Liu L; Morawski BM; Schymura M; Schwartz SM; Ward KC; Wiggins C; Wu XC; Shoag JE; Ponsky L; Dal Pra A; Schaeffer EM; Ross AE; Sun Y; Davicioni E; Petkov V; Spratt DE
    JNCI Cancer Spectr; 2023 Aug; 7(5):. PubMed ID: 37525535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer.
    Press BH; Jones T; Olawoyin O; Lokeshwar SD; Rahman SN; Khajir G; Lin DW; Cooperberg MR; Loeb S; Darst BF; Zheng Y; Chen RC; Witte JS; Seibert TM; Catalona WJ; Leapman MS; Sprenkle PC
    Eur Urol Open Sci; 2022 Mar; 37():113-119. PubMed ID: 35243396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
    Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
    Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
    BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
    Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis.
    Lee HJ; Yousefi K; Haddad Z; Abdollah F; Lam LL; Shin H; Alshalalfa M; Godebu E; Wang S; Shabaik A; Davicioni E; Kane CJ
    Res Rep Urol; 2016; 8():77-84. PubMed ID: 27419104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
    Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
    J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
    Cooperberg MR; Erho N; Chan JM; Feng FY; Fishbane N; Zhao SG; Simko JP; Cowan JE; Lehrer J; Alshalalfa M; Kolisnik T; Chelliserry J; Margrave J; Aranes M; Plessis MD; Buerki C; Tenggara I; Davicioni E; Carroll PR
    Eur Urol; 2018 Oct; 74(4):444-452. PubMed ID: 29853306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.